While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...
The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...
The FDA granted elraglusib a rare pediatric disease designation for Ewing sarcoma based on findings from the 1/2 Actuate-1902 trial. The FDA granted a rare pediatric disease designation to elraglusib ...
Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...
At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell ...
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an ...
Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback